Andrew Brohl

Medical Oncologist and Rare Cancer Researcher. #sarcoma #merkelcellcarcinoma

[Jonathan Zager, MD @jzager99]

Lacey Mead presenting results after neoadjuvant IO for Merkel cell carcinoma, and how well the patients do. Demonstrating an overall response rate of 75% and complete major path response of 60%. Great work. More to come as we do more with neoadjuvant and MCC @ASCO @MoffittNews

[Dr. Bui Pathologist🌼 @DrBuiPathology]

🎤Please check out my new publication! https://t.co/f9LV9KwMAB

[Moffitt Cancer Center @MoffittNews]

At #ASCO25, Mihaela Druta, MD, (@MihaelaDruta) and Andrew Brohl, MD, (@AndrewBrohl) discuss emerging science on Merkel cell carcinoma and sarcoma.
#MoffittASCO25

[Moffitt Cancer Center @MoffittNews]

🚨Breaking Science from #ASCO25. Kenneth Tsai, MD, PhD, (@KYTsaiLab) joined us to discuss new data from the C-POST trial on adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma. Details ⬇️

Read more: https://t.co/ovURg1DWre
#MoffittASCO25 @ASCO

[Mihaela Druta @MihaelaDruta]

Enjoying #ASCO25 so far! Congrats to @AndrewBrohl on his oral presentation on neoadjuvant lenvatinib + pembrolizumab in MCC. Results highlight the potential for new combination therapies and biomarkers. We also filmed a chat about exciting sarcoma breakthroughs! #MoffittASCO25

[Moffitt Cancer Center @MoffittNews]

Today at #ASCO25, Andrew Brohl, MD, (@AndrewBrohl) discusses an immunotherapy combo showing promise as a pre-surgical treatment for Merkel cell carcinoma.

Read more: https://t.co/t6xlYiwK2K

#MoffittASCO25 @ASCO

[Moffitt Cancer Center @MoffittNews]

https://t.co/22HWMBasjd

[Moffitt Cancer Center @MoffittNews]

LIVE from #ASCO25: Andrew Brohl, MD, (@AndrewBrohl) shares promising results from a phase II study neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.

Key findings:
• Pembrolizumab plus Lenvatinib had encouraging efficacy as neoadjuvant therapy for resectable clinical stage II-IV Merkel cell carcinoma (MCC).
👉Pathological complete response (pCR) rate = 57.7% (15 of 26).
👉Progression free survival (PFS) - median not reached; 23.1% (6 of 26) progression with 20 months follow-up.

• Toxicity profile similar to that reported with this combination for other approved indications.
👉TRAES - 54% with G3 toxicity, most commonly G3 HTN (42%).

• Demonstrates the feasibility of a combination neoadjuvant study in MCC.

• Efficacy of Pembrolizumab plus Lenvatinib in MCC requires further confirmation.

Read more: https://t.co/xaWjVLoDN1

#MoffittASCO25

[Dr. Patrick Hwu @PatrickHwuMD]

Now in the #melanoma rapid oral presentation at #ASCO25: Moffitt’s own Andrew Brohl, MDA (@AndrewBrohl) presents phase II results on neoadjuvant lenvatinib + pembrolizumab in resectable clinical stage I–IV Merkel cell carcinoma.

Key conclusions:

➡️ Promising efficacy: 57.7% pCR rate; PFS not yet reached at 20-month follow-up
➡️ Safety profile consistent with known data: Grade 3 HTN (42%), Grade 3 rAEs (12%)
➡️ Supports feasibility of neoadjuvant trials in high-risk MCC
➡️ Further clinical/translational research needed to define role

#MerkelCell #Immunotherapy #Neoadjuvant @ASCO #MoffittASCO25 @MoffittNews

[Moffitt Cancer Center @MoffittNews]

Join Andrew Brohl, MD, (@AndrewBrohl) tomorrow at #ASCO25 as he discusses a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.

Read more: https://t.co/D0YPNHOWJQ
#MoffittASCO25 @ASCO

[Moffitt Cancer Center @MoffittNews]

From #ASCO25: Andrew Brohl, MD (@AndrewBrohl) presents a randomized trial evaluating IFx-Hu2.0 plus pembrolizumab as first-line therapy in advanced Merkel cell carcinoma. The study explores a novel innate immune agonist to boost checkpoint inhibitor response. #MoffittASCO25

[Moffitt Cancer Center @MoffittNews]

LIVE from #SITC24, Marian Smallin (@MSciAdventures) joins us to discuss how the chromosome 19 microRNA cluster promotes TIL-based immune evasion in #melanoma. #MoffittSITC24

Learn more ➡️ https://t.co/p1ahKIImDC
@sitcancer

[John E. Mullinax, MD, FACS @JohnEMullinaxMD]

Our #sarcoma medical oncology leader @MihaelaDruta gave an outstanding talk today on the translational endpoints from the SPEARHEAD-1 trial. @MoffittNews @Adaptimmune #SITC2024 #MoffittSITC24

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma https://t.co/u8nnE5bBYC @VernSondakMD @DrKhushalani @AndrewBrohl

[Moffitt Cancer Center @MoffittNews]

During #ASCO24, Andrew Brohl, MD (@AndrewBrohl) joined Patrick Hwu, MD (@PatrickHwuMD) to discuss the latest in Merkel cell carcinoma. #MoffittASCO24

[Moffitt Cancer Center @MoffittNews]

During #ASCO24, Andrew Brohl, MD (@AndrewBrohl) joined Patrick Hwu, MD (@PatrickHwuMD) to discuss the latest in Merkel cell carcinoma. #MoffittASCO24

[Moffitt Cancer Center @MoffittNews]

At #ASCO24, Andrew Brohl, MD (@AndrewBrohl) discusses the latest in Merkel cell carcinoma & cutaneous squamous cell carcinoma treatments. #MoffittASCO24

Learn more: https://t.co/9MEFBj75I2
@ASCO

[Moffitt Cancer Center @MoffittNews]

Andrew Brohl, MD (@AndrewBrohl) joins us to discuss the durability of immune checkpoint inhibitor response following treatment discontinuation in advanced Merkel cell carcinoma at #ASCO24. #MoffittASCO24

[Moffitt Cancer Center @MoffittNews]

At #ASCO24, Andrew Brohl, MD (@AndrewBrohl) discusses a personalized vaccine that shows promise in Merkel cell carcinoma. #MoffittASCO24
https://t.co/IGLdikJ3Uj

[Alex Soupir @AlexSoupir]

Further understanding the tumor environment to shed light on differences in histological subtypes and patient survival. Wonderful study @oscareospina